Masimo Corp. today reported study data showing that its pulse oximetry technology accurately monitored hospitalized newborns of all skin tones without dangerous drops in blood oxygen.
The findings come from what the Irvine-based company described as the largest-ever prospective real-world study of its kind, having evaluated 100 newborns.
“Concerns about occult hypoxemia in vulnerable neonates, especially with darker skin tones, prompted this large, investigator-initiated and NIH funded real-world study applying rigorous scientific methods,” Masimo’s Chief Medical Officer Daniel Cantillon said in a statement.
Later this year, Masimo said that it will publish data from another study involving 500 critically ill adult ICU patients of all skin tones.
Shares in Masimo were little changed today at $178.45 apiece and a $9.3 billion market cap (Nasdaq: MASI).
